Chengdu, China, October 19, 2026 — Chengdu New Radiomedicine Technology Co., Ltd. (“NRT”) today announced that its Class I radiopharmaceutical, 90Y-NRT6020 Injection, has received implicit clinical trial approval from the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). This approval allows NRT to initiate a clinical trial of the product in patients with FAP-positive advanced malignant solid tumors.
This is the third radionuclide-labeled product in the NRT6020 program to receive clinical trial approval, following 68Ga-NRT6020 and 177Lu-NRT6020. It is also NRT’s first Yttrium-90 (90Y)-labeled Radioligand Therapy (RLT) candidate to receive clinical trial approval.
With this approval, the NRT6020 program now spans three complementary radionuclide candidates—diagnostic imaging, beta-emitting therapy, and longer-range beta-emitting therapy—making it one of a small number of FAP-targeted radiopharmaceutical platforms in China with this integrated theranostic approach.
Targeting FAP-positive tumors
Fibroblast activation protein (FAP) is highly expressed by cancer-associated fibroblasts (CAFs) in the tumor microenvironment and is found in more than 90% of epithelial-derived tumors. Because of its broad presence across tumor types and limited expression in healthy tissues, FAP is regarded as a promising target for both diagnostic imaging and radioligand therapy.
As an important component of NRT’s FAP-targeted theranostic pipeline, the clinical trial approval of 90Y-NRT6020 strengthens the program’s three radionuclides theranostic strategy and marks another milestone in the company’s development of FAP-targeted RLT products.
